Expression of V1A and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition

British Journal of Cancer

Volumn 92, Issue 3, 2005, Pages 522-531

  MacKinnon, A C ^a   Tufail Hanif, U ^a   Lucas, C D ^a   Jodrell, D ^b   Haslett, C ^a   Sethi, T ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

GRP; SCLC; SP D; SP G; Transformation; Vasopressin

Indexed keywords

ARGIPRESSIN; ARGIPRESSIN RECEPTOR; ETOPOSIDE; GASTRIN RELEASING PEPTIDE; GASTRIN RELEASING PEPTIDE RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPEPTIDE; PERTUSSIS TOXIN; SUBSTANCE P; SUBSTANCE P [6-11]; SUBSTANCE P DERIVATIVE; UNCLASSIFIED DRUG; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V1A RECEPTOR; NEUROPEPTIDE RECEPTOR; PEPTIDE FRAGMENT;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CANCER INHIBITION; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOTOXICITY; LUNG SMALL CELL CANCER; METASTASIS; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CELL CULTURE; CELL DIVISION; CRICETULUS; GENETIC TRANSFECTION; GENETICS; HAMSTER; HUMAN; METABOLISM;

ANIMALS; ARGININE VASOPRESSIN; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CRICETINAE; CRICETULUS; ETOPOSIDE; GASTRIN-RELEASING PEPTIDE; HUMANS; PEPTIDE FRAGMENTS; RECEPTORS, NEUROPEPTIDE; SUBSTANCE P; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 15244345165     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602366     Document Type: Article

References (43)

1. Abel A, Wittau N, Wieland T, Schultz G, Kalkbrenner F (2000) Cell cycle-dependent coupling of the vasopressin Via receptor to different G proteins. J Biol Chem 275: 32543-32551
2. Bajo AM, Schally AV, Krupa M, Hebert F, Groot K, Szepeshazi K (2002) Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes. Proc Natl Acad Sci 99: 3836-3841
3. Benya RV, Akeson M, Mrozinski J, Jensen RT, Battey JF (1994) Internalization of the gastrin-releasing peptide receptor is mediated by both phospholipase C-dependent and -independent processes. Mol Pharmacol 46: 495-501
4. Carroll RE, Matkowskyj KA, Chakrabarti S, McDonald TJ, Benya RV (1999) Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans. Am J Physiol 276: G655-G665
5. Chaudhry A, Carrasquillo JA, Avis IL, Shuke N, Reynolds JC, Bartholomew R, Larson SM, Cuttitta F, Johnson BE, Mulshine JL (1999) Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res 5: 3385-3393
6. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108
7. Clive S, Webb DJ, MacLellan A, Young A, Byrne B, Robson L, Smyth JF, Jodrell DI (2001) Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist. Clin Cancer Res 10: 3071-3078
8. Coulson JM, Ocejo-Garcia M, Woll PJ (2003) Neuroendocrine phenotype of small cell lung cancer. Methods Mol Med 74: 61-73
9. DeBlasi A, O'Reilly K, Motulsky HJ (1989) Calculating receptor number from binding experiments using same compound as radioligand and competitor. Trends Pharmacol Sci 6: 227-229
10. Della Rocca GJ, Maudsley S, Daaka Y, Lefkowitz RJ, Luttrell LM (1999) Pleiotropic coupling of G protein-coupled receptors to the mitogen-activated protein kinase cascade. Role of focal adhesions and receptor tyrosine kinases. J Biol Chem 274: 13978-13984
11. De Vincentis G, Remediani S, Varvarigou AD, Di Santo G, Iori F, Laurenti C, Scopinaro F (2004) Role of 99mTc-Bombesin scan in diagnosis and staging of prostate cancer. Cancer Biother Radiopharm 19: 81-84
12. Djanani A, Kaneider NC, Sturn D, Wiedermann CJ (2003) Agonist function of the neurokinin receptor antagonist, [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-substance-P, in monocytes. Regul Pept 115: 123-129
13. Ferris HA, Carroll RE, Rasenick MM, Benya RV (1997) Constitutive activation of the gastrin-releasing peptide receptor expressed by the nonmalignant human colon epithelial cell line NCM460. J Clin Invest 100: 2530-2537
14. Friedmann AS, Malott KA, Memoli VA, Pai SI, Yu XM, North WG (1994) Products of vasopressin gene expression in small-cell carcinoma of the lung. Br J Cancer 69: 260-263
15. Glover S, Delaney M, Dematte C, Kornberg L, Frasco M, Tran-Son-Tay R, Benya RV (2004) Phosphorylation of focal adhesion kinase tyrosine 397 critically mediates gastrin-releasing peptide's morphogenic properties. Cell Physiol 199: 77-88
16. Jarpe MB, Knall C, Mitchell FM, Buhl AM, Duzic E, Johnson GL (1998) [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J Biol Chem 273: 3097-3104
17. Jensen JA, Carroll RE, Benya RV (2001) The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 22: 689-699
18. Jensen RT, Jones SW, Folkers K, Gardner JD (1984) A synthetic peptide that is a bombesin receptor antagonist. Nature 309: 61-63
19. Johnson BE, Chute JP, Rushin J, Williams J, Le PT, Venzon D, Richardson GE (1997) A prospective study of patients with lung cancer and hyponatremia of malignancy. Am J Respir Crit Care Med 156: 1669-1678
20. Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino AL, Varga (2003) JL Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Proc Natl Acad Sci 100: 15836-15841
21. Keegan BP, Memoli VA, North WG (2002) Targeting the neurophysin-related cell surface antigen on small cell lung cancer cells using a monoclonal antibody against the glycopeptide region (MAG-1) of provasopressin. Mol Cancer Ther 1: 1153-1159
22. Koppan M, Halmos G, Arencibia JM, Lamharzi N, Schally AV (1998) Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma. Cancer 83: 1335-1343
23. Kuroda H, Mandai M, Konishi I, Yura Y, Tsuruta Y, Hamid AA, Nanbu K, Matsushita K, Mori T (1998) Human chorionic gonadotropin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: possible role of up-regulation of insulin-like growth factor-1 by hCG. Int J Cancer 76: 571-578
24. Langdon S, Sethi T, Ritchie A, Muir M, Smyth J, Rozengurt E (1992) Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vivo. Cancer Res 52: 4554-4557
25. 8]- substance-P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant dependent mechanism. Br J Cancer 80: 1026-1034
26. MacKinnon AC, Waters C, Jodrell D, Haslett C, Sethi T (2001) Bombesin and substance-P analogues differentially regulate G-protein coupling to the bombesin receptor. Direct evidence for biased agonism. J Biol Chem 276: 28083-28091
27. Moody TW, Pert CB, Gazdar AF, Carney DN, Minna JD (1981) High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science 214: 1246-1248
28. North WG (2000) Gene regulation of vasopressin and vasopressin receptors in cancer. Exp Physiol 83: 27S-40S
29. Ocejo-Garcia M, Ahmed SI, Coulson JM, Woll PJ (2001) Use of RT-PCR to detect co-expression of neuropeptides and their receptors in lung cancer. Lung Cancer 33: 1-9
30. Profrock A, Zimmermann P, Schulz I. (1992) Bombesin receptors interact with Gi and p21ras proteins in plasma membranes from rat pancreatic acinar cells. Am J Physiol 263: G240-G247
31. Ravi RK, Weber E, McMahon M, Williams JR, Baylin S, Mal A, Harter ML, Dillehay LE, Claudio PP, Giordano A, Nelkin BD, Mabry M (1998) Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest 101: 153-159
32. Seckl MJ, Newman RH, Freemont PS, Rozengurt E (1995) Substance-P-related antagonists inhibit vasopressin and bombesin but not 5′-3-O-(thio) triphosphate-stimulated inositol phosphate production in Swiss 3T3 cells. J Cell Physiol 163: 87-95
33. Seifert R, Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn-Schmiedeberg's Arch Pharmacol 366: 381-416
34. Sethi T, Langdon SP, Smyth JS, Rozengurt E (1992) Growth of small cell lung cancer cells, stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo. Cancer Res 52: 2737s-2742s
35. Sethi T, Rozengurt E (1991) Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin, and neurotensin. Cancer Res 51: 3621-3623
36. Sinnett-Smith J, Santiskulvong C, Duque J, Rozengurt E (2000) [D-Arg(1),D-Trp(5,7,9),Leu(11)]Substance-P inhibits bombesin-induced mitogenic signal transduction mediated by both G(q) and G(12) in Swiss 3T3cells. J Biol Chem 275: 30644-30652
37. Smyth JF, Fowlie SM, Gregor A, Crompton GK, Busutill A, Leonard RCF, Grant IWB (1986) The impact of chemotherapy on small cell carcinoma of the bronchus. Quart J Med 61: 969-976
38. Strakova Z, Kumar A, Watson AJ, Soloff MS. (1997) A new linear V1A vasopressin antagonist and its use in characterizing receptor/G protein interactions. Mol Pharmacol 51: 217-224
39. Sumitomo M, Milowsky MI, Shen R, Navarro D, Dai J, Asano T, Hayakawa M, Nanus DM (2001) Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res 61: 3294-3298
40. Tallet A, Chilvers ER, Hannah S, Dransfield I, Lawson MF, Haslett C, Sethi T (1996) Inhibition of neuropeptide-stimulated tyrosine phosphorylation and tyrosine kinase activity stimulates apoptosis in small cell lung cancer cells. Cancer Res 56: 4255-4263
41. Waters CM, MacKinnon AC, Cummings J, Tufail-Hanif U, Jodrell D, Haslett C, Sethi T (2003) Increased gastrin-releasing peptide (GRP) receptor expression in tumour cells confers sensitivity to [Arg6,D-Trp7,9,NmePhe8]-substance-P (6-11)-induced growth inhibition. Br J Cancer 88: 1808-1816
42. Wetzker R, Bohmer FD (2003) Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol 4: 651-657
43. 11]-substance-P a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of small cell lung cancer in vitro. Proc Nat Acad Sci 85: 1859-1863